Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the ...

Let’s delve into the details of each of the evaluated factors, but first, for a quick background: With a $917 Bil market cap, ...

Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...

Eli Lilly and Company’s LLY stock crossed the $1000 per share mark for the first time on Nov. 12, reaching new highs. It is ...

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump ...

Even by dramatically lowering the prices of some of its medications, the drug giant is still outpacing its rivals and nearing ...

South Korea’s newest billionaire is Lee Sang-hoon, founder of ABL Bio, after it struck a $2.6 billion licensing and joint ...

Eli Lilly is poised to become the first $1 trillion pharmaceutical company, driven by explosive growth in its weight-loss ...

Eli Lilly stock has regained all-time highs, outpacing rivals in the obesity drug market. Click here to read my latest ...

Lilly's tirzepatide is sold as Mounjaro for Type 2 diabetes and as Zepbound for weight loss -- but doctors have prescribed ...

Pharmaceutical giant Eli Lilly and Co. is bringing its next Gateway Labs to Philadelphia. Here's where and why.

Eli Lilly CEO David Ricks said he prefers to use xAI's Grok and Anthropic's Claude over ChatGPT for science-related questions ...